The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
May 17th 2024
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Data Support Safety, Effectiveness of Biosimilar-to-Biosimilar Switching
August 3rd 2022Although there is a paucity of data of switching among biosimilars of the same reference product, the few studies published support the safety and effectiveness of transitioning patients from one biosimilar to another.
Read More
Medicines for Europe: Off-Patent Medicines Could Strengthen Europe’s Health Systems
July 21st 2022During its annual conference in Spain, Medicines for Europe shared recommendations for greater use of off-patent medications, such as biosimilars and generics, as a way ensure medicines remain available to patients in light of global events and supply chain issues.
Read More
Ophthalmologists See Promise and Peril, but Lack Familiarity, With Biosimilars
July 19th 2022Until recently, ophthalmologists in the United States have had no experience with biosimilars, despite the availability of biosimilars for bevacizumab, which is commonly used off label for ophthalmic conditions.
Read More
Most Patients Received Inadequate Information on Switching to Biosimilars, Survey Finds
July 12th 2022A survey of patients with breast cancer and oncologists found that when switching to a trastuzumab biosimilar from the reference product (Herceptin), many patients were not given adequate information on what biosimilars are and their benefits.
Read More
Real-World Outcomes Explored in Studies of Bevacizumab Biosimilar for Metastatic Colorectal Cancer
July 2nd 2022Abstracts presented at the 2022 American Society of Clinical Oncology Annual Meeting show bevacizumab-awwb to be safe and effective for patients with metastatic colorectal cancer (mCRC) with high overall survival rates.
Read More
Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds
June 24th 2022Among a real-world cohort of patients, switching between infliximab biosimilars was effective and well tolerated, although retention was higher among those who had initially started on the originator product.
Read More
Biosimilar Utilization Increased During the OCM and Generated Savings
June 23rd 2022Abstracts presented at the American Society of Clinical Oncology Annual Meeting evaluated biosimilar use in practices participating in the Oncology Care Model (OCM) and estimated the savings as a result of substituting these agents for more expensive reference products.
Read More
Dr Sonia Oskouei Highlights the Need to Align Incentives to Promote Use of Biosimilars
May 27th 2022Alignment of incentives in the United States do not always support the use of biosimilars or other lower-cost alternatives, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
Watch
Dr Sonia Oskouei on Managed Care’s Impact After Rollout of Adalimumab Biosimilars
May 16th 2022While 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
Watch
Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei
May 12th 2022Biosimilar adoption can be accelerated or stymied depending on actions taken by the managed care space, explained Sonia Oskouei, PharmD, vice president, biosimilars, Cardinal Health, during a session at Asembia’s Specialty Pharmacy Summit.
Read More
Dr Gillian Woollett Highlights International Markets With Successful Biosimilar Adoption
April 29th 2022Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, gives insight into what international markets the United States could look to as examples of good biosimilar adoption.
Watch